Radiopharmaceutical developer Navidea Biopharmaceuticals announced it has appointed a new chief medical officer (CMO).
Dr. Cornelia Reininger, PhD, has been named CMO of the firm, effective November 1.
Reininger joins Navidea from Bayer HealthCare Pharmaceuticals, where she was senior director of clinical research and global clinical leader for the company's Alzheimer's development programs. At Bayer, she managed clinical development from phase I through phase III and the registration filings of the company's PET neuroimaging agent florbetaben. Reininger has also worked at GE Healthcare and Amersham Health, Navidea said.
